Good evening :)
$
₹
K

Kyntra Bio, Inc.

KYNB

NASDAQ
K

Kyntra Bio, Inc.

KYNB

NASDAQ
$4.511.53% (-0.07)
$
₹
$4.511.53% (-0.07)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Micro Cap

With a market cap of $18.5M the stock is ranked 5451

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

80.39
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-7.64
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

3968.63%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
4 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+740.59%

Earnings Growth

-127.29%

Rev. Growth

-0.27%

See Detailed Forecast

Company Profile

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.
Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was formerly known as FibroGen, Inc. and change its name to Kyntra Bio, Inc. in January 2026. Kyntra Bio, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

2026
Current$4.58Baseline
Analyst Target - 1 year
Target$38.5+740.59%

All values in $

20232024202520262027$13.68$23.24$32.79Target+740.59%
2026
Current$4.58Baseline
Analyst Target - 1 year
Target$38.5+740.59%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -0.27% growth, versus a trailing 3-year CAGR of -64.23%.

2025
Current$6.44Baseline
Forecast for Dec 2026
High$8.9+38.2%
Average$6.42-0.27%
Low$4.8-25.47%

All values in $ Million

202120222023202420252026235.30140.7346.8029.626.44Low-25.47%Average-0.27%High+38.2%
2025
Current$6.44Baseline
Forecast for Dec 2026
High$8.9+38.2%
Average$6.42-0.27%
Low$4.8-25.47%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$45.47Baseline
Forecast for Dec 2026
High$-12.41-127.29%
Average$-12.41-127.29%
Low$-12.41-127.29%

All values in $

202120222023202420252026-78.5-45.38-56.3-11.745.47Low-127.29%Average-127.29%High-127.29%
2025
Current$45.47Baseline
Forecast for Dec 2026
High$-12.41-127.29%
Average$-12.41-127.29%
Low$-12.41-127.29%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

1
148.4
1.2
37.9
3.7
-15.1
-1.4
11.9
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue25.360.9946.33-123.252.731.341.071.273.73-1.47
Net Income-32.93-15.54-17.0817.984.63-7.60148.4737.94-15.1911.97
Net Profit Margin-129.84%-1557.51%-36.87%-14.58%169.36%-564.02%13798.60%2971.26%-406.58%-812.34%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Kyntra Bio, Inc. -80.39-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare KYNB with any stock or ETF
Compare KYNB with any stock or ETF
Comparing from
KYNB
ABBV
AMGN
Loading...

Frequently asked questions

  1. Kyntra Bio, Inc. (KYNB) share price today is $4.51 as of October 26, 2026 at 11:05 PM IST. The stock touched a day high of $4.86 and a day low of $4.35.

  2. Kyntra Bio, Inc. stock trades on NASDAQ under the ticker symbol KYNB.

  3. Kyntra Bio, Inc.'s market capitalization is $18.54M as of October 26, 2026 at 11:05 PM IST.

  4. Kyntra Bio, Inc.'s price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Kyntra Bio, Inc.'s price-to-book (P/B) ratio is 80.39 as of October 26, 2026.

  6. Yes, You can buy Kyntra Bio, Inc. shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Kyntra Bio, Inc. shares in three steps: 1. Search Kyntra Bio, Inc. on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Kyntra Bio, Inc. trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Kyntra Bio, Inc. (KYNB) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 2.2172 shares at the current price of $4.51.

Loading...